Champeaux C, Jecko V
Service de neurochirurgie, hôpital Sainte-Anne, 1, rue Cabanis, 75014 Paris, France; Service de neurochirurgie, hôpital Pellegrin, 33000 Bordeaux, France.
Service de neurochirurgie, hôpital Pellegrin, 33000 Bordeaux, France.
Neurochirurgie. 2016 Aug;62(4):203-8. doi: 10.1016/j.neuchi.2016.05.001. Epub 2016 Jun 20.
To depict the outcome of patients with WHO grade III meningioma and identify factors that may influence the survival.
Between 1989 and 2007, a retrospective search identified 43 WHO grade III meningiomas after cases exclusion. Nine patients (39.5%) had a previous history of grade I or II meningioma. The patients underwent a total of 89 surgical resections and 83.7% received radiotherapy. Median follow-up was 7.4 years.
At the end of the study, 35 patients were deceased (81.4%). One patient died of disseminated metastatic disease of a papillary meningioma. Median overall survival was 4.1 years, 95% CI [1.9, 8.3]. Overall survival probability at 1, 5 and 10 years were respectively: 81.4%, 95% CI [70.6, 93.9], 48.8%, 95% CI [36,66.3] and, 27.5%, 95% CI [16.9, 44.9]. In univariate Cox regression, a previous surgery for WHO grade I or II meningioma (HR=2.05, 95% CI [1.03, 4.07], P=0.04) and the mitosis count (HR=0.3, 95% CI [0.12, 0.79], P=0.02) were associated with the overall survival. However, neither macroscopic gross total resection (HR=0.87, 95% CI [0.4, 1.87], P=0.71), nor radiotherapy (HR=0.75, 95% CI [0.31, 1.83], P=0.53) was associated with an increased survival.
This series highlights the poor prognosis associate with the diagnosis of malignant meningioma. Patients with primary WHO grade III meningioma demonstrating less than 14 mitosis per 10 high power fields may live longer. We could not confirm the usefulness of complete resection and adjuvant radiotherapy.
描述世界卫生组织(WHO)III级脑膜瘤患者的预后情况,并确定可能影响生存的因素。
在1989年至2007年期间,通过回顾性检索,排除病例后确定了43例WHO III级脑膜瘤。9例患者(39.5%)有I级或II级脑膜瘤病史。患者共接受了89次手术切除,83.7%接受了放疗。中位随访时间为7.4年。
研究结束时,35例患者死亡(81.4%)。1例患者死于乳头状脑膜瘤的播散性转移疾病。中位总生存期为4.1年,95%置信区间[1.9, 8.3]。1年、5年和10年的总生存概率分别为:81.4%,95%置信区间[70.6, 93.9];48.8%,95%置信区间[36, 66.3];27.5%,95%置信区间[16.9, 44.9]。在单因素Cox回归分析中,既往有WHO I级或II级脑膜瘤手术史(风险比[HR]=2.05,95%置信区间[1.03, 4.07],P=0.04)和有丝分裂计数(HR=0.3,95%置信区间[0.12, 0.79],P=0.02)与总生存期相关。然而,肉眼全切(HR=0.87,95%置信区间[0.4, 1.87],P=0.71)和放疗(HR=0.75,95%置信区间[0.31, 1.83],P=0.53)均与生存期延长无关。
本系列研究突出了恶性脑膜瘤诊断所伴随的不良预后。每10个高倍视野有丝分裂少于14个的原发性WHO III级脑膜瘤患者可能存活时间更长。我们无法证实全切和辅助放疗的有效性。